Source: Pharamceutical Technology

Seres Therapeutics: Seres' SER-155 gains breakthrough status for BSIs reduction

Seres Therapeutics has received US FDA breakthrough therapy designation for its SER-155, aimed at decreasing BSIs.

Read full article »
Seres Therapeutics's Competitors | Seres Therapeutics's News | Seres Therapeutics's Financials
Stay up-to-date with the latest news on Seres Therapeutics
Annual Revenue
$100-500M
Employees
100-250
Eric D. Shaff's photo - President & CEO of Seres Therapeutics

President & CEO

Eric D. Shaff

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on Seres Therapeutics